The latest announcement is out from CASI Pharmaceuticals ( (CASI) ).
On April 3, 2025, CASI Pharmaceuticals announced receiving an updated non-binding proposal from its Chairman and CEO, Dr. Wei-Wu He, to acquire the company’s entire business operations in China and related rights in Asia, excluding Japan, for $20 million. This proposal, which updates a previous one from June 2024, includes assuming $20 million in company debt. The company’s board has formed a special committee to evaluate this proposal and any alternative strategic options. However, no decisions have been made, and there is no assurance of a definitive agreement or transaction approval, impacting stakeholders’ considerations.
More about CASI Pharmaceuticals
CASI Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and globally. The company specializes in hematology oncology therapeutics, organ transplant rejection, autoimmune diseases, and other unmet medical needs, leveraging its China-based regulatory and commercial competencies and global drug development expertise.
YTD Price Performance: -29.19%
Average Trading Volume: 14,876
Technical Sentiment Signal: Strong Buy
Current Market Cap: $28.14M
See more data about CASI stock on TipRanks’ Stock Analysis page.